Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/4636s587

ROLE OF REGENERATIVE MEDICINE IN ORTHOPEDICS OSTEOMYELITIS.

Dr Gautam Kashyap[1], Dr Deepak Ghritlahre[2], Dr Champa Singh Kanwar[3*]

[1]Assistant Professor, Department of Orthopedics, CCMGMCH Durg, (C.G)
[2]Assistant Professor, Department of Orthopedics, SBDMS Medical College Korba, (C.G)
[3*]Assistant Professor, Department of Orthopedics, SBDMS Medical College Korba, (C.G)

***Corresponding Author**- Dr Champa Singh Kanwar
*Assistant Professor, Department of Orthopedics, SBDMS Medical College Korba, (C.G). Email- champs.kanwar11@gmail.com, Mobile No- 8770477859.

Abstract
This study aimed to evaluate the efficacy and safety of regenerative medicine compared to conventional orthopedic treatments in a randomized controlled trial. The research focused on pain reduction, functional improvement, range of motion, and patient satisfaction. Participants were randomly assigned to either the Regenerative Medicine Group, receiving treatments such as stem cell therapy and platelet-rich plasma (PRP) injections, or the Control Group, which received standard orthopedic care. Major findings revealed that the Regenerative Medicine Group experienced significantly greater reductions in pain, improved functional outcomes, enhanced range of motion, and higher patient satisfaction compared to the Control Group. These results suggest that regenerative therapies offer superior benefits over traditional treatments, providing more effective pain management and functional recovery. The study concludes that regenerative medicine has the potential to transform orthopaedic care by addressing both symptoms and underlying conditions more effectively. Future research should focus on long-term outcomes, cost-effectiveness, and optimizing treatment protocols.

Keywords: *Regenerative Medicine, Orthopaedics, Stem Cell Therapy, Platelet-Rich Plasma, Randomized Controlled Trial*

Introduction

Regenerative medicine represents a rapidly evolving frontier in medical science, with significant implications for the field of orthopaedics. This innovative approach focuses on the restoration or replacement of damaged tissues and organs through the application of biological therapies. The premise of regenerative medicine lies in harnessing the body's inherent capacity for self-healing and repair, aiming to not only alleviate symptoms but also address the underlying pathophysiology of musculoskeletal disorders. This methodology includes various techniques such as stem cell therapy, platelet-rich plasma (PRP) injections, and tissue engineering, each offering unique mechanisms for tissue regeneration and repair.

Orthopaedic conditions, including osteoarthritis, rheumatoid arthritis, and traumatic injuries, often lead to significant functional impairment and diminished quality of life. Conventional treatments typically focus on symptom management, including medications, physical therapy, and surgical interventions. While these methods can provide relief and improve function, they frequently fall short

in addressing the root causes of joint degeneration and damage. This limitation underscores the need for advanced therapeutic strategies that not only mitigate symptoms but also promote long-term recovery and restoration of normal function

Stem cell therapy, a cornerstone of regenerative medicine, has garnered substantial attention due to its potential to regenerate damaged cartilage, bone, and other tissues. By utilizing cells that possess the ability to differentiate into various cell types, this approach aims to repair or replace damaged tissues. Similarly, PRP therapy leverages growth factors derived from the patient's own blood to stimulate healing and tissue repair. These approaches are designed to enhance the body's natural healing processes, offering a more holistic solution compared to traditional treatments.

The integration of regenerative medicine into orthopaedic practice offers several potential benefits. First, by addressing the underlying biological processes that contribute to joint damage, these therapies could potentially slow or even reverse the progression of degenerative conditions. Second, regenerative treatments are generally less invasive than traditional surgical interventions, which can reduce recovery times and associated complications. Moreover, personalized applications of these therapies allow for tailored treatments based on individual patient needs and specific disease characteristics.

Despite the promising potential of regenerative medicine, there remains a need for rigorous scientific evaluation to validate its efficacy and safety. Clinical trials and studies are essential to assess the impact of these therapies on pain reduction, functional improvement, and overall patient satisfaction. Such evaluations are critical for establishing evidence-based protocols and ensuring that regenerative treatments provide tangible benefits over conventional methods.

The focus of current research is to understand how regenerative medicine can be effectively utilized in orthopaedics to address common challenges such as joint pain, reduced mobility, and functional limitations. By comparing regenerative therapies to traditional treatments, researchers aim to provide clearer insights into their relative effectiveness and identify the optimal approaches for different patient populations.

Regenerative medicine holds significant promise for advancing orthopaedic care by offering innovative solutions that target the root causes of musculoskeletal disorders. As research continues to elucidate the benefits and limitations of these therapies, it is crucial to build a robust evidence base that supports their integration into standard clinical practice. Through ongoing studies and clinical trials, the field of regenerative medicine is poised to transform the management of orthopaedic conditions, providing hope for improved outcomes and enhanced quality of life for patients.

Research Gap

Despite the advancements in regenerative medicine, a significant research gap persists in understanding its full potential and comparative effectiveness within the realm of orthopaedics. While regenerative therapies, such as stem cell treatments and platelet-rich plasma (PRP) injections, have shown promise in preliminary studies, there is a need for comprehensive, high-quality evidence to establish their efficacy and safety across diverse patient populations. Current literature is often limited by small sample sizes, short follow-up periods, and a lack of rigorous control groups, leading to inconclusive or mixed results regarding the benefits of regenerative medicine compared to conventional orthopaedic treatments.

Most existing studies have focused on isolated outcomes, such as pain relief or functional improvement, without providing a holistic view of how these therapies impact multiple facets of patient health and well-being. Additionally, there is limited research on the long-term outcomes of regenerative treatments, including their effects on joint health, mobility, and overall quality of life over extended periods. This gap highlights the necessity for well-designed, randomized controlled trials that can address these limitations and provide a more robust understanding of the benefits and potential drawbacks of regenerative medicine.

Another critical aspect of the research gap involves the variability in treatment protocols and patient responses. Different studies employ varying methodologies, dosages, and treatment regimens, making it challenging to draw generalized conclusions or establish standardized guidelines for practice.

Furthermore, the underlying mechanisms of action for many regenerative therapies remain poorly understood, which complicates the ability to predict outcomes and tailor treatments effectively.
Finally, patient satisfaction and subjective experiences with regenerative therapies have not been thoroughly examined in many studies. Understanding how patients perceive the effectiveness of these treatments and their overall satisfaction is essential for evaluating their real-world applicability and integrating them into clinical practice.
Addressing these gaps requires comprehensive research that not only evaluates the clinical efficacy of regenerative therapies but also examines their long-term effects, patient satisfaction, and the impact of different treatment protocols. Such studies are crucial for advancing the field of regenerative medicine and ensuring that it delivers meaningful benefits to patients with orthopaedic conditions.

Specific Aims of the Study

The primary aim of this study is to evaluate the efficacy and safety of regenerative medicine in comparison to conventional treatment methods for orthopaedic conditions. This evaluation will be conducted through a rigorous, randomized controlled trial involving 400 participants divided equally between two groups: the Regenerative Medicine group and the Control Group.

1. **Assess the Effectiveness of Regenerative Medicine**: This aim focuses on determining how well regenerative therapies, including stem cell treatments and PRP injections, reduce pain, improve functional outcomes, and enhance range of motion compared to standard orthopaedic treatments. By measuring pain reduction through Visual Analog Scale (VAS), functional improvement through WOMAC scores, and range of motion, the study aims to provide a comprehensive assessment of the therapeutic efficacy of regenerative medicine.
2. **Evaluate Long-Term Outcomes**: A key objective is to examine the long-term effects of regenerative treatments on patient health, including sustained pain relief, functional improvements, and overall quality of life. This involves assessing outcomes at multiple time points (1, 3, and 6 months) to understand the durability of the treatment benefits and any potential long-term impacts on joint health and mobility.
3. **Compare Patient Satisfaction**: The study aims to evaluate patient satisfaction with regenerative medicine versus conventional treatments. By using standardized satisfaction surveys, the study seeks to capture patients' subjective experiences and overall satisfaction with their treatment, which is crucial for understanding the real-world applicability and acceptability of regenerative therapies.
4. **Analyze Variability in Treatment Responses**: Another aim is to investigate how different patients respond to regenerative therapies and identify factors that may influence treatment outcomes. This includes examining variations in efficacy based on patient demographics, clinical characteristics, and treatment protocols to provide insights into optimizing treatment strategies.

Objectives of the Study

1. **To Quantitatively Measure Pain Reduction**: Using the VAS score, the study will objectively measure changes in pain levels over time in both the Regenerative Medicine and Control Groups. This objective aims to determine whether regenerative therapies offer superior pain relief compared to conventional treatments.
2. **To Assess Functional Improvement**: By employing the WOMAC index, the study will evaluate improvements in pain, stiffness, and functional limitations. This objective focuses on understanding the impact of regenerative medicine on daily activities and overall functional status.
3. **To Evaluate Range of Motion Enhancements**: The study will measure improvements in joint flexibility using a goniometer. This objective aims to determine if regenerative therapies contribute to better range of motion compared to traditional treatments.
4. **To Determine Patient Satisfaction Rates**: Through standardized surveys, the study will assess patient satisfaction with the treatment received. This objective aims to gauge the overall patient experience and satisfaction with regenerative medicine versus conventional treatments.
5. **To Analyze Treatment Protocol Variability**: The study will investigate how different treatment regimens and patient characteristics influence outcomes. This objective seeks to identify factors that

may affect the effectiveness of regenerative therapies and provide insights into personalized treatment approaches.

Hypothesis

The primary hypothesis of this study is that regenerative medicine is more effective than conventional orthopaedic treatments in improving patient outcomes. Specifically, it is hypothesized that:

1. Pain Reduction: The Regenerative Medicine Group will exhibit significantly greater reductions in pain levels, as measured by the VAS score, compared to the Control Group at all follow-up time points (1, 3, and 6 months).

2. Functional Improvement: Patients receiving regenerative therapies will show greater improvements in functional outcomes, as assessed by the WOMAC index, compared to those receiving conventional treatments.

3. Range of Motion: The Regenerative Medicine Group will demonstrate significantly greater enhancements in joint range of motion compared to the Control Group.

4. Patient Satisfaction: The Regenerative Medicine Group will report higher satisfaction rates compared to the Control Group, reflecting a more favorable overall treatment experience.

5. Treatment Protocol Variability: Variability in treatment responses will be observed, with certain patient demographics and treatment regimens showing more pronounced benefits from regenerative therapies. This variability will provide insights into optimizing treatment approaches and personalizing care.

Research Methodology

Study Design

This study utilizes a prospective, randomized controlled trial (RCT) design to evaluate the efficacy and safety of regenerative medicine in orthopaedics compared to conventional treatment methods. The study enrolled 400 participants, equally divided into two groups: the Regenerative Medicine group (n = 200) and the Control Group (n = 200).

Participants

Participants were recruited from outpatient clinics specializing in orthopaedic disorders. Eligibility criteria included individuals with primary diagnoses of osteoarthritis, rheumatoid arthritis, or requiring fracture repair. All participants provided informed consent prior to inclusion. Exclusion criteria were those with contraindications for regenerative therapies, severe comorbidities, or prior treatments that could confound the results.

Interventions

The Regenerative Medicine group received a standard protocol of regenerative therapy, including treatments such as Platelet-Rich Plasma (PRP) injections or stem cell therapy, depending on the specific diagnosis and clinical protocol. The Control Group received conventional treatment, which included medications, physical therapy, and standard surgical interventions as needed.

Outcome Measures

1. Pain Reduction (VAS Score):

- **Measurement**: Participants' pain levels were assessed using the Visual Analog Scale (VAS) at baseline, 1 month, 3 months, and 6 months.
- **Importance**: Pain reduction is a primary indicator of treatment efficacy in orthopaedic disorders. A significant reduction in VAS scores in the Regenerative Medicine group compared to the Control Group would suggest superior pain management and efficacy of the regenerative treatment.

2. Functional Improvement (WOMAC Score):

- **Measurement**: Functional outcomes were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and at 6 months.

- **Importance**: The WOMAC score assesses pain, stiffness, and functional limitations. Improvement in WOMAC scores reflects better functional status and quality of life, making it a critical measure of the regenerative medicine's impact on daily activities and overall functionality.

3. Range of Motion (Degrees):
- **Measurement**: Range of motion was quantified using a goniometer at baseline and 6 months.
- **Importance**: Range of motion is an essential indicator of joint function and mobility. Enhanced range of motion in the Regenerative Medicine group compared to the Control Group would indicate a positive effect of the regenerative treatments on joint flexibility and overall functional improvement.

4. Patient Satisfaction Rates:
- **Measurement**: Patient satisfaction was assessed through a standardized survey at 6 months.
- **Importance**: Patient satisfaction captures the subjective experience of the treatment. High satisfaction rates in the Regenerative Medicine group would not only validate the objective findings of improved pain and function but also indicate a favorable overall treatment experience.

Data Analysis

Statistical analyses were performed to compare outcomes between the Regenerative Medicine and Control Groups. Descriptive statistics were used to summarize participant demographics and baseline characteristics. Inferential statistics, including t-tests and ANOVA, were applied to evaluate differences in pain reduction, functional improvement, range of motion, and patient satisfaction between the two groups. A significance level of $p < 0.05$ was used for all statistical tests.

Significance

The chosen measures and methods provide a comprehensive evaluation of the regenerative medicine's effectiveness in managing orthopaedic conditions. By comparing pain reduction, functional improvements, range of motion, and patient satisfaction, the study offers a multidimensional view of treatment impact. This approach not only quantifies clinical outcomes but also assesses the overall patient experience, providing valuable insights into the potential benefits and limitations of regenerative medicine in orthopaedics.

Results

This study evaluated the efficacy of regenerative medicine in orthopaedics through a randomized controlled trial (RCT) with 400 participants, divided equally into a Regenerative Medicine group and a Control Group. The following results detail the outcomes based on pain reduction, functional improvement, range of motion, and patient satisfaction.

1. Pain Reduction

Pain reduction was assessed using the Visual Analog Scale (VAS) at baseline, 1 month, 3 months, and 6 months.

Table 1: Pain Reduction Over Time

Time Point (Months)	Regenerative Medicine Group (VAS Score, Mean ± SD)	Control Group (VAS Score, Mean ± SD)	p-value
0	7.5 ± 1.0	7.4 ± 1.1	0.75
1	6.0 ± 1.1	6.5 ± 1.2	0.22
3	4.5 ± 1.2	5.5 ± 1.3	<0.01
6	2.5 ± 1.3	3.8 ± 1.4	<0.001

Table 1 illustrates the average VAS pain scores over time for the Regenerative Medicine and Control Groups. The Regenerative Medicine Group demonstrated a significantly greater reduction in pain scores at 3 and 6 months compared to the Control Group.



Figure 1: Pain Reduction Over Time

Figure 1 shows the average pain reduction (VAS Score) over a 6-month period. The Regenerative Medicine Group exhibits a more pronounced decrease in pain compared to the Control Group.

2. Functional Improvement

Functional outcomes were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at baseline and 6 months.

Table 2: Functional Improvement (WOMAC Score) Comparison

Group	WOMAC Score (Mean ± SD)	p-value
Regenerative Medicine	40.3 ± 8.5	<0.001
Control Group	55.2 ± 9.1	

Table 2 compares WOMAC scores between the Regenerative Medicine and Control Groups at 6 months. The Regenerative Medicine Group achieved significantly better functional improvement.



Figure 2: Functional Improvement (WOMAC Score) Comparison

Figure 2 compares WOMAC scores between the groups. The Regenerative Medicine Group shows superior functional improvement compared to the Control Group.

3. Range of Motion

Range of motion was measured in degrees using a goniometer at baseline and 6 months.

Table 3: Range of Motion Improvements

Group	Range of Motion (Degrees, Mean ± SD)	p-value
Regenerative Medicine	135.2 ± 12.3	<0.01
Control Group	125.1 ± 14.6	

Table 3 presents the range of motion improvements for both groups. The Regenerative Medicine Group showed a significant increase in range of motion compared to the Control Group.



Figure 3: Range of Motion Improvements

Figure 3 illustrates the improvement in range of motion from baseline to 6 months. The Regenerative Medicine Group demonstrated greater gains compared to the Control Group.

4. Patient Satisfaction Rates

Patient satisfaction was assessed through a standardized survey at 6 months.

Table 4: Patient Satisfaction Rates

Group	Satisfaction Rate (%)	p-value
Regenerative Medicine	85.0	<0.001
Control Group	60.0	

Table 4 shows patient satisfaction rates for both groups. The Regenerative Medicine Group reported significantly higher satisfaction rates.



Figure 4: Patient Satisfaction Rates

Figure 4 depicts patient satisfaction rates as a percentage. The Regenerative Medicine Group had a higher satisfaction rate compared to the Control Group.

Statistical Analysis

Inferential statistical analyses, including t-tests and ANOVA, were used to evaluate differences between the two groups in terms of pain reduction, functional improvement, range of motion, and patient satisfaction. A significance level of $p < 0.05$ was employed for all tests. The results indicate:

- **Pain Reduction**: Significant reductions in VAS scores were observed at 3 and 6 months for the Regenerative Medicine Group, suggesting superior efficacy in pain management.
- **Functional Improvement**: The Regenerative Medicine Group demonstrated a significant improvement in WOMAC scores compared to the Control Group, reflecting better functional outcomes.
- **Range of Motion**: The Regenerative Medicine Group showed significantly greater improvement in range of motion, indicating enhanced joint flexibility.
- **Patient Satisfaction**: The Regenerative Medicine Group reported significantly higher satisfaction rates, supporting the overall effectiveness and favorable patient experience with regenerative treatments.

These results collectively highlight the benefits of regenerative medicine in orthopaedics, offering significant advantages in pain relief, functional improvement, and patient satisfaction compared to conventional treatments.



Figure 5: Summary Figure with new results

Conclusion

The study was designed to evaluate the hypothesis that regenerative medicine would outperform conventional orthopaedic treatments in terms of pain reduction, functional improvement, range of motion, and patient satisfaction. The results largely supported this hypothesis. The Regenerative Medicine Group demonstrated significant improvements in pain reduction, as evidenced by lower Visual Analog Scale (VAS) scores over time, compared to the Control Group. Similarly, functional outcomes, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), showed notable enhancements in the regenerative group. Range of motion improvements were also more pronounced in the Regenerative Medicine Group, reflecting better joint flexibility. Furthermore, patient satisfaction rates were significantly higher among those receiving regenerative treatments. These findings affirm that regenerative medicine offers superior benefits compared to conventional orthopaedic treatments, validating the initial hypothesis and highlighting its potential as a more effective therapeutic approach.

Limitations of the Study

Despite the promising results, the study has several limitations. First, while the sample size of 400 participants provides substantial power, it is still limited by the variability in patient responses and the specific treatment protocols used. Variations in treatment regimens and patient demographics may affect the generalizability of the results. Second, the study's follow-up period of 6 months, while sufficient for assessing short- to mid-term outcomes, does not capture the long-term durability of regenerative therapies. Extended follow-up would be necessary to evaluate the sustainability of treatment effects and any potential delayed adverse outcomes. Third, the study was limited by its reliance on subjective measures, such as patient-reported pain and satisfaction scores, which can be influenced by individual perceptions and reporting biases. Incorporating objective measures, such as imaging or biomarkers, could provide a more comprehensive assessment of treatment effects. Lastly, the study did not explore the cost-effectiveness of regenerative therapies compared to conventional treatments, which is an important consideration for clinical decision-making and healthcare policy.

Implications of the Study

The study's findings have significant implications for clinical practice and patient care in orthopaedics. The demonstrated superiority of regenerative medicine in pain reduction, functional improvement, and patient satisfaction suggests that these therapies could become a preferred option for managing various orthopaedic conditions. The ability to address underlying joint degeneration and provide longer-lasting relief aligns with the growing demand for effective, minimally invasive treatments. The

positive patient satisfaction rates also indicate that regenerative therapies are well-received, which could influence patient preferences and treatment choices. Additionally, the results provide valuable evidence for clinicians and policymakers in considering the integration of regenerative medicine into standard practice. By highlighting the benefits and effectiveness of these therapies, the study supports the need for continued investment in research and development to further refine and optimize regenerative treatment protocols.

Future Recommendations

To build on the study's findings, several future research directions are recommended. First, conducting larger-scale studies with diverse patient populations and longer follow-up periods would help confirm the long-term efficacy and safety of regenerative therapies. Future research should also focus on understanding the mechanisms underlying the observed benefits, such as the biological processes involved in tissue repair and regeneration. This knowledge could lead to more targeted and effective treatment strategies. Second, incorporating objective outcome measures, such as advanced imaging techniques or biomarkers, would enhance the assessment of treatment effects and provide a more comprehensive evaluation. Third, exploring the cost-effectiveness of regenerative therapies compared to conventional treatments is essential for assessing their economic viability and informing healthcare decision-making. Finally, investigating the impact of different treatment protocols and patient characteristics on outcomes could lead to personalized treatment approaches that maximize the benefits of regenerative medicine. By addressing these areas, future research can further validate and optimize regenerative therapies, ultimately improving patient care and advancing the field of orthopaedics.

References

1. Atala, A., et al. (2006) Tissue-Engineered Autologous Bladders for Patients Needing Cystoplasty. *The Lancet*, 367, 1241-1246.
2. Baiguera, S., Birchall, M.A. and Macchiarini, P. (2010) Tissue-Engineered Tracheal Transplantation. *Transplantation*, 89, 485-491.
3. Blundell, J. (1818) Experiments on the Transfusion of Blood by the Syringe. *Medico-Chirurgical Transactions*, 9, 56-92.
4. Daar, A.S. and Greenwood, H.L. (2007) A Proposed Definition of Regenerative Medicine. *Journal of Tissue Engineering and Regenerative Medicine*, 1, 179-184.
5. Goodarzi, P., et al. (2018) Tissue Engineered Skin Substitutes. *Advances in Experimental Medicine and Biology*, 1107, 143-188.
6. Hoffman, T., Khademhosseini, A. and Langer, R. (2019) Chasing the Paradigm: Clinical Translation of 25 Years of Tissue Engineering. *Tissue Engineering Part A*, 25, 679-687.
7. Jacques, E. and Suuronen, E.J. (2020) The Progression of Regenerative Medicine and Its Impact on Therapy Translation. *Clinical and Translational Science*, 13, 440-450.
8. Kessler, M.W. and Grande, D.A. (2008) Tissue Engineering and Cartilage. *Organogenesis*, 4, 28-32.
9. Kobayashi, E. and Haga, J. (2016) Translational Microsurgery. A New Platform for Transplantation Research. *Acta Cirúrgica Brasileira*, 31, 212-217.
10. Macchiarini, P., et al. (2008) Clinical Transplantation of a Tissue-Engineered Airway. *The Lancet*, 372, 2023-2030.
11. Mason, C. and Dunnill, P. (2008) A Brief Definition of Regenerative Medicine. *Regenerative Medicine*, 3, 1-5.
12. Murray, J.E., Merrill, J.P. and Harrison, J.H. (1958) Kidney Transplantation between Seven Pairs of Identical Twins. *Annals of Surgery*, 148, 343-359.
13. Orlando, G., et al. (2011) Regenerative Medicine as Applied to Solid Organ Transplantation: Current Status and Future Challenges. *Transplant International*, 24, 223-232.
14. Orlando, G., et al. (2011) Regenerative Medicine and Organ Transplantation: Past, Present, and Future. *Transplantation*, 91, 1310-1317.

15. Plotner, A.N. and Mostow, E.N. (2010) A Review of Bioactive Materials and Chronic Wounds. *Cutis*, 85, 259-266.
16. Raya-Rivera, A., et al. (2011) Tissue-Engineered Autologous Urethras for Patients Who Need Reconstruction: An Observational Study. *The Lancet*, 377, 1175-1182.
17. Risbud, M.V. and Sittinger, M. (2002) Tissue Engineering: Advances in in Vitro Cartilage Generation. *Trends in Biotechnology*, 20, 351-356.
18. Shimmura, S. and Tsubota, K. (2003) Regeneration of the Cornea. *Nihon Rinsho*, 61, 475-479.
19. Sommer, F., Brandl, F. and Göpferich, A. (2006) Ocular Tissue Engineering. *Advances in Experimental Medicine and Biology*, 585, 413-429.
20. Sohier, J., et al. (2008) Critical Factors in the Design of Growth Factor Releasing Scaffolds for Cartilage Tissue Engineering. *Expert Opinion on Drug Delivery*, 5, 543-566.
21. Yang, Z., Xie, H. and Li, T. (2000) Tissue Engineering of the Musculo-Skeletal System—Basic Research and Clinical Applications. *Journal of Hand Surgery*, 5, 49-55.
22. Jadlowiec, C.C. and Taner, T. (2016) Liver Transplantation: Current Status and Challenges. *World Journal of Gastroenterology*, 22, 4438-4445.